DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
                   
tmcnet.com     May 22, 2008            

EWING, NJ, May 22 / MARKET WIRE/ -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism... [read full story]                    


View all news articles about*:
Ambulatory America BioPharma Biopharmaceuticals Cancer Cancers Care DOR Ewing Health Jersey Medical Medicines North Patients Pharmaceuticals Remedies Research States Treatments United Vaccines
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Back-To-School Checkups Provide Key Immunizations

wcbstv.com     52 mins ago          

No matter what grade your child is about to enter, there's a yearly checklist of back-to-school "to-do's." At the top of the list is the pediatric checkup. Much more than just filling out the school forms, it's a vital part of...                    

comments

                   

The Gardasil Hustle

gooznews.com     1 hr ago   13 related          

The day after the New York Times unveiled a masterful exposé of Merck's marketing campaign for the cervical cancer vaccine Gardasil, the New England Journal of Medicine published a cost-effectiveness analysis that questions the...                    

comments

Nearly 150 Are Dead in Madrid Plane Crash

drudgereport.com     2 hrs ago          

By CAROLINE BROTHERS 5:18 PM ET Nearly 150 people were killed Wednesday when an airliner en route to the Canary Islands swerved off the end of a runway at Madrid’s airport during takeoff, officials said. Researchers Question...                    

comments

                   

Cervical cancer shots less cost-effective with age

iht.com     2 hrs ago   26 related          

An expensive vaccine aimed at preventing cervical cancer makes sense for young teens when it comes to cost-effectiveness, but not for women in their 20s, contends a new report. The vaccine against the HPV virus was licensed in...                    

comments